Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1990-08-24
1992-12-29
Cashion, Jr., Merrell C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530307, 530324, A61K 3702, A61K 3730, C07K 500, C07K 700
Patent
active
051751461
ABSTRACT:
Synthetic hypocalcemic peptides which are similar in biological properties to native calcitonins as clinically useful agents. The peptides comprise analogues of native calcitonins having amino acid substitutions and deletions which act to improve potency, prolong duration of the hormonal effect, enhance receptor binding, and increase oral or nasal bioavailability. The calcitonin peptide analogues are less expensive and more easily synthesized than native calcitonins, and have improved resistance to inactivation or degradation. Methods are provided for the synthesis of these peptides.
Also, disclosed are novel cyclic peptides, including calcitonin, having increased stability with respect to proteolysis. Methods for the synthesis of these peptides are provided, comprising converting disulfide cyclic peptides and proteins to enzymatically and chemically stable cyclic peptide structures by the replacement of cysteine residues with dicarboxylic acids and diamino acids. The method is applicable to various naturally occurring peptides, their synthetic analogues or derivatives, and proteins.
REFERENCES:
patent: 3910872 (1975-10-01), Riniker et al.
patent: 4397780 (1983-08-01), Orlowski et al.
patent: 4613500 (1986-09-01), Suzuki et al.
patent: 4622386 (1986-11-01), Orlowski et al.
patent: 4639510 (1987-01-01), Orlowski
patent: 4659804 (1987-04-01), Orlowski et al.
patent: 4663309 (1987-05-01), Kaiser et al.
patent: 4758550 (1988-07-01), Cardinaux et al.
Channabasavaiah et al., Biochem. Biophys. Res. Commun., 86, pp. 1266-1273 (1979).
Kaiser et al., Science, 223, pp. 249-255, 1984.
Kaiser, E. T. et al., Anal. Biochem. 34:595-598, (1969).
Kumar, M. et al., J. Endocrinology 33:469-475 (1964).
Liedtke, Clinical Chemistry, 27, 2025-2028 (1981).
Lasmoles et al. The EMBO Journal 4(10):2603-2607 (1985).
Breimer, L. H., MacIntyre, I., and Zaidi, M., Biochem. J. 255:377 390 (1988).
Marx et al., Science 178:998-1001 (1972).
Epand et al., Biochemistry 25:1964-1968 (1988).
Habener et al., Nature (London) 232:91-92 (1971).
Pietta, P. G. and G. R. Marshall, J. Chem. Soc. D, 650-651 (1970).
Basava Channa
Hostetler Karl Y.
Cashion Jr. Merrell C.
Davenport A. M.
Vical Inc.
LandOfFree
Synthetic calcitonin peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synthetic calcitonin peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthetic calcitonin peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1887115